| 查看: 212 | 回复: 0 | |||
| 当前主题已经存档。 | |||
shich68木虫 (著名写手)
|
[交流]
成体骨髓间充质干细胞的多能性
|
||
|
我们在此报道的细胞是与基质干细胞共分离、纯化得到的，并把其称之为多能性成体祖细胞或MAPCs。这种细胞的单个细胞在体外不仅可分化为间充质细胞，而且可以分化为具有中胚层、神经外胚层和外胚层细胞特征的细胞。把这些细胞注入早期囊胚后，单个MAPCs可以分化为绝大多数类型的体细胞；当这些细胞移入非射线照射的宿主体内后，MAPCs除可以分化为肝上皮、肺上皮和肠上皮细胞外，还可以定植并分化为造血家系的细胞；当这些细胞移入最低量射线照射的宿主体内后，它们既可在消化道定植又可以在造血系统定植。由于MAPCs具有强大的增值能力，而没有明显的衰老或分化潜能的降低，所以它们可以作为遗传性或退行性疾病治疗的理想细胞来源。 原文在Narure上的出版日期：NATURE |VOL 418 | 4 JULY 2002 | www.nature.com/nature/nature © 2002 Nature Publishing Group Pluripotency of mesenchymal stem cells derived from adult marrow Yuehua Jiang*†, Balkrishna N. Jahagirdar*†‡, R. Lee Reinhardt§, Robert E. Schwartz*, C. Dirk Keenek, Xilma R. Ortiz-Gonzalezk, Morayma Reyes*, Todd Lenvik*, Troy Lund*, Mark Blackstad*, Jingbo Du*, Sara Aldrich*, Aaron Lisberg*, Walter C. Lowk, David A. Largaespada{ & Catherine M. Verfaillie*‡ * Stem Cell Institute, ‡ Division of Hematology, Oncology and Transplantation, Department of Medicine, § Department of Microbiology, Center for Immunology, k Department of Neurosurgery, and { Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA † These authors contributed equally to this work We report here that cells co-purifying with mesenchymal stem cells—termed here multipotent adult progenitor cells or MAPCs—differentiate, at the single cell level, not only into mesenchymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro. When injected into an early blastocyst, single MAPCs contribute to most, if not all, somatic cell types. On transplantation into a non-irradiated host, MAPCs engraft and differentiate to the haematopoietic lineage, in addition to the epithelium of liver, lung and gut. Engraftment in the haematopoietic system as well as the gastrointestinal tract is increased when MAPCs are transplanted in a minimally irradiated host. As MAPCs proliferate extensively without obvious senescence or loss of differentiation potential, they may be an ideal cell source for therapy of inherited or degenerative diseases. |
回复此楼» 猜你喜欢
膀胱癌靶向治疗新选择：厄达替尼作用机制与耐药研究进展
已经有0人回复
-
从水母到实验室：腔肠素的发现历程与生物发光奥秘
已经有1人回复
-
化学工程及工业化学论文润色/翻译怎么收费?
已经有62人回复
-
线粒体氧化磷酸化的新靶点：S-Gboxin的发现与研究进展
已经有0人回复
-
PROTAC药物开发选择VHL配体：MDK-7526以87%出口向量占有率成首选
已经有0人回复
-
MCC950：NLRP3炎症小体特异性抑制剂的科研应用与前景
已经有0人回复
-
康替唑胺研发17年：如何解决多重耐药菌感染难题
已经有0人回复
-
伊曲莫德（Etrasimod）从“肠道免疫失控”到精准靶向干预
已经有1人回复
-
西达本胺：创新HDAC抑制剂的抗肿瘤之路
已经有0人回复
-
金色抗生素单硫酸卡那霉素的物化性质、制备与前景
已经有0人回复